Connection

Co-Authors

This is a "connection" page, showing publications co-authored by LUHUA WANG and JING YANG.
Connection Strength

0.802
  1. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504.
    View in: PubMed
    Score: 0.114
  2. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8.
    View in: PubMed
    Score: 0.100
  3. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60.
    View in: PubMed
    Score: 0.078
  4. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85.
    View in: PubMed
    Score: 0.076
  5. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell. 2007 Sep; 12(3):252-65.
    View in: PubMed
    Score: 0.075
  6. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007 Oct 15; 110(8):3028-35.
    View in: PubMed
    Score: 0.075
  7. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15; 109(12):5455-62.
    View in: PubMed
    Score: 0.073
  8. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006 Oct; 10(4):295-307.
    View in: PubMed
    Score: 0.071
  9. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83.
    View in: PubMed
    Score: 0.028
  10. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92.
    View in: PubMed
    Score: 0.027
  11. Targeting cell surface ?2 -microglobulin by pentameric IgM antibodies. Br J Haematol. 2011 Jul; 154(1):111-21.
    View in: PubMed
    Score: 0.024
  12. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009 Oct 22; 114(17):3625-8.
    View in: PubMed
    Score: 0.022
  13. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Oct 29; 114(18):3880-9.
    View in: PubMed
    Score: 0.022
  14. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.